Established and emerging oral antifungals in dermatology

Dermatologic, Cosmeceutic, and Cosmetic Development: Therapeutic and Novel Approaches

Volumn , Issue , 2007, Pages 283-296

  Piérard, Gérald E ^a   Piérard Franchimont, Claudine ^a   Vroome, Valérie ^b   Arrese, Jorge ^a   Quatresooz, Pascale ^a   Borgers, Marcel ^b,c   Cauwenbergh, Geert ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Barrier Therapeutics NV   (Belgium)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d Barrier Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72249107152     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (82)

1. Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003; 207:255-260.
2. De Doncker P. Pharmacokinetics of orally administered antifungals in onychomycosis. Int J Dermatol 1999; 38:S10-S27.
3. Arrese JE, De Doncker P, Odds F, Piérard GE. Reduction in the growth of nondermatophyte moulds by itraconazole: evaluation by corneofungimetry bioassay. Mycoses 1998; 41:461-465.
4. Arrese JE, Pierard-Franchimont C, Piérard GE. A plea to bridge the gap between antifungals and onychomycosis management. Am J Clin Dermatol 2001; 2:281-284.
5. Osborne CS, Leitner I, Favre B, Ryder NS. Antifungal drug response in an in vitro model of dermatophyte nail infection. Med Mycol 2004; 42:159-163.
6. Baran R, Gupta AK, Piérard GE. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother 2005; 6:609-624.
7. Gupta AK, Tomas E. New antifungal agents. Dermatol Clin 2003; 21:565-576.
8. Borgers M, Degreef H, Cauwenbergh G. Fungal infections of the skin: infection process and antimycotic therapy. Curr Drug Targets 2005; 6:849-862.
9. Piérard GE, Rurangirwa A, Piérard-Franchimont C. Bioavailability of fluconazole and ketoconazole in human stratum corneum and oral mucosa. Clin Exp Dermatol 1991; 16:168-171.
10. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and man. Antimicrob Agents Chemother 1985; 28:648-653.
11. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24:10-27.
12. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycosis in toenails with fluconazole 150 mg once weekly. Acta Derm Venereol 1996; 76:219-221.
13. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999; 141:S26-S32.
14. Gupta AK, Katz HI, Shear NH. Drug interactions with itraconazole, fluconazole and terbinafine and their management. J Am Acad Dermatol 1999; 41:237-249.
15. Shear N, Drake L, Gupta A, et al. The implications and management of drug interactions with itraconazole, fluconazole and terbinafine. Dermatology 2000; 201:196-203.
16. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450s. J Am Acad Dermatol 2002; 47:467-484.
17. Pierard GE, Arrese JE, Pierard-Franchimont C. Treatment of onychomycosis. Traditional approaches. J Am Acad Dermatol 1993; 29:S41-S45.
18. Sloboda RD, Van Blaricom G, Creasey WA, et al. Griseofulvin: association with tubulin and inhibition of in vitro microtubule assembly. Biochem Biophys Res Commun 1982; 105:882-888.
19. Schäfer-Korting M, Korting HC, Mutschler E. Human plasma and skin blister fluid levels of griseofulvin following a single oral dose. Eur J Clin Pharmacol 1985; 29:109-113.
20. Bates TR, Sequeira JAL. Use of 24 hr urinary excretion to assess the bioavailability of griseofulvin in humans. J Pharm Sci 1975; 64:709.
21. Van Cutsem J, Van Gerven F, Janssen PAJ. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models. Rev Infect Dis 1987; 9:S15-S32.
22. Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole. Exp Opin Pharmacother 2000; 1:287-304.
23. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents:a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
24. Piérard GE, Arrese JE, De Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32:429-435.
25. Piérard GE, Kharfi M, Salomon-Neira MD, et al. Itraconazole in human aspergillosis revisited. J Mycol Med 2004; 14:192-200.
26. Piérard GE, Arrese JE, Pierard-Franchimont C. Itraconazole corneofungimetry bioassay on Malassezia species. Mycoses 2004; 47:418-421.
27. Warnock DW, Turner A, Burke J. Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole. J Antimicrob Chemother 1988; 21:93-100.
28. Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18:263-268.
29. De Doncker PD, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol 1996; 132:34-41.
30. De Doncker P, Scher R, Baran R, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 73-177.
31. Havu V, Brandt H, Heikkila H, et al. Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison. Br J Dermatol 1999; 140:96-101.
32. De Doncker P, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1998; 37: 969-974.
33. Haneke E, Abeck D, Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail-onychomycosis: a multicentre trial. Mycoses 1998; 41:521-527.
34. Wang DL, Wang AP, Li RY, Wang R. Therapeutic efficacy and safety of one-week intermittent therapy with itraconazole for onychomycosis in a Chinese patient population. Dermatology 1999; 199:47-19.
35. Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 2000; 15(5):112-115.
36. Gupta AK, Maddin S, Arlette J, et al. Itraconazole pulse therapy is effective in dermatophyte onychomycosis of the toenail: a double-blind placebo-controlled study. J Dermatol Treat 2000; 11:33-37.
37. Ginter-Hanselmeyer G, Smolle J, Gupta A. Itraconazole in the treatment of tinea capitis caused by Microsporum canis: experience in a large cohort. Pediatr Dermatol 2005;22:499-502.
38. Havu V, Brandt H, Heikkila H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136:230-234.
39. Ingber A. Intermittent low dose itraconazole treatment for onychomycosis-long term follow-up. Med Mycol 2001; 39:471-473.
40. Barone JA, Moskovitch BL, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob Agents Chemother 1998; 42:1862-1865.
41. Van De Velde VJS, Van Peer AP, Heykants JJP, et al. Effects of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996; 16:424-428.
42. Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clin Infect Dis 1998; 28:250-255.
43. Glasmacher A, Haln C, Molitor E, et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regiments using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42:591-600.
44. Stevens DA. Itraconazole in cyclodextrin solution. Pharmacotherapy 1999; 19:603-611.
45. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44:343-500.
46. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-180.
47. Gupta AK, Chwetzoff E, Del Rosso J, Baran R. Hepatic safety of itraconazole. J Cutan Med Surg 2002; 6:210-213.
48. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357:1716-1717.
49. Arrese JE, Fogouang L, Piérard-Franchimont C, Pierard GE. Euclidean and fractal computer-assisted corneofungimetry. A comparison of 2% ketoconazole and 1% terbinafine topical formulations. Dermatology 2002; 204:222-227.
50. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microb 2001; 39:4208-4209.
51. Gupta AK, Kohli Y, Batra R. In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 2005; 43:179-185.
52. Odds F, Ausma J, Van Gerven F, et al. Activity in vitro and in vivo activities of the novel azole antifungal agent R126638. Antimicrob Agents Chemother 2004; 48:388-391.
53. Vanden Bossche H, Ausma J, Bohets H, et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. and Microsporum canis. Antimicrob Agents Chemother 2004; 48:3272-3278.
54. Meerpoel L, Backx LJJ, van der Veken LJE, et al. Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. J Med Chem 2005; 48:2184-2193.
55. Piérard-Franchimont C, Ausma J, Wouters L, et al. Activity of the triazole antifungal R126638 as assessed by corneofungimetry. Skin Pharmacol Physiol 2006; 19:49-56.
56. Faergemann J, Ausma J, Borgers M. The in vitro activity of R126638 and ketoconazole against Malassezia species. Acta Dermatol Venereol 2006; 86:312-315.
57. Piérard GE, Ausma J, Henry F, et al. A pilot study on seborrheic dermatitis using pramiconazole as a potent oral anti-Malassezia agent. Dermatology 2007; 214:162-169.
58. Fung-Tome JC, Huezko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998; 42:313-318.
59. Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol 2005; 19:437-443.
60. Jenssen JC. Pharmacokinetics of terbinafine in humans. J Dermatol Treat 1990; 1:S15-S18.
61. Faergemann J, Zehender H, Boukhabza A et al. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol 1997; 77:74-76.
62. Schatz F, Brautigam M, Bobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20:377-383.
63. Finlay AY, Lever LR, Thomas R, Dykes PJ. Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1:S51-S54.
64. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br. J. Dermatol. 1992, 126: S28-S32.
65. Evans G, Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. Br Med J 1999; 318:1031-1035.
66. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy: J Am Acad Dermatol 1996; 34(4):595-600.
67. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungal) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol 2004; 140:691-695.
68. Gupta AK, Del Rosso JQ. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol 2000; 39:401-411.
69. Piérard GE, Arrese JE, Quatresooz P, Pierard-Franchimont C. Voriconazole (Vfen®). Rev Med Liège 2003; 58:351-355.
70. Van Loo D. Voriconazole: an evaluation of activity and use. J Infect Dis Pharmacother 2003; 6:15-37.
71. Racette AJ, Roenigk HH, Hansen R, et al. Photoaging and phototoxicity from long-term voriconazole treatment in a 15-year-old girl. J Am Acad Dermatol 2005; 52:82-85.
72. Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44:485-491.
73. Medoff G, Kobayashi GS, Kwang CN, et al. Potentialisation of rifampicin and flucocytosine as antifungal antibiotics by amphotericin B. Proc Soc Exp Biol Med 1971; 138:571-574.
74. Polack A. The past, present and future of antimycotic combination therapy. Mycoses 1999; 42:355-370.
75. Rubin MA, Carroll KC, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34:1160-1161.
76. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003, 37:S188-S224.
77. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98:292-299.
78. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995; 39:1907-1912.
79. Bohme A, Just-Nubling G, Bergmann L, et al. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1999; 42:443-451.
80. Santos DA, Hamdan JS. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes. Med Mycol 2006; 44:357-362.
81. Faergemann J. Atopic dermatitis and fungi. Clin Microbiol Rev 2002; 15:545-563.
82. Nikkels AF, Pierard GE. Framing the future of antifungals in atopic dermatitis. Dermatology 2003; 206:398-400.